New Biosimilar Approvals for Myeloid Growth Factors and Anemia.

New Biosimilar Approvals for Myeloid Growth Factors and Anemia. J Natl Compr Canc Netw. 2019 May 01;17(5.5):622-624 Authors: Lyman GH Abstract Biosimilars are here to stay, but whether they will enjoy widespread uptake remains to be seen. The FDA sets a high bar for approval of biosimilar products, yet many clinicians remain skeptical about the efficacy and safety of these agents. Favorable experience with >30 biosimilars in Europe provides some reassurance that these agents are safe and effective and can be substituted for the reference product. PMID: 31117042 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research